Smith & Nephew SNATS Net Change in Property, Plant, and Equipment 2010-2024 | SNN
Smith & Nephew SNATS annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2024. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- Smith & Nephew SNATS net change in property, plant, and equipment for the quarter ending December 31, 2024 was $-0.381B, a 120.23% increase year-over-year.
- Smith & Nephew SNATS net change in property, plant, and equipment for the twelve months ending December 31, 2024 was $-1.333B, a 11.18% increase year-over-year.
- Smith & Nephew SNATS annual net change in property, plant, and equipment for 2024 was $-0.381B, a 10.77% decline from 2023.
- Smith & Nephew SNATS annual net change in property, plant, and equipment for 2023 was $-0.427B, a 19.27% increase from 2022.
- Smith & Nephew SNATS annual net change in property, plant, and equipment for 2022 was $-0.358B, a 12.25% decline from 2021.
| Smith & Nephew SNATS Annual Net Change in Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2024 | $-381 |
| 2023 | $-427 |
| 2022 | $-358 |
| 2021 | $-408 |
| 2020 | $-443 |
| 2019 | $-408 |
| 2018 | $-347 |
| 2017 | $-376 |
| 2016 | $-392 |
| 2015 | $-358 |
| 2014 | $-355 |
| 2013 | $-340 |
| 2012 | $-265 |
| 2011 | $-321 |
| 2010 | $-307 |
| 2009 | $-318 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $13.214B | $5.810B |
| Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $215.166B | 25.24 |
| Boston Scientific (BSX) | United States | $153.330B | 38.38 |
| Stryker (SYK) | United States | $148.630B | 31.08 |
| EssilorLuxottica (ESLOY) | France | $131.070B | 0.00 |
| Medtronic (MDT) | Ireland | $114.929B | 16.29 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.764B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.126B | 24.61 |
| ResMed (RMD) | United States | $37.818B | 28.41 |
| GE HealthCare Technologies (GEHC) | United States | $34.781B | 16.51 |
| Agilent Technologies (A) | United States | $32.381B | 21.11 |
| Terumo (TRUMY) | Japan | $23.911B | 31.06 |
| Koninklijke Philips (PHG) | Netherlands | $23.688B | 16.62 |
| Insulet (PODD) | United States | $20.003B | 78.52 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.437B | 11.84 |
| Baxter (BAX) | United States | $14.251B | 10.64 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.705B | 23.33 |
| Lantheus Holdings (LNTH) | United States | $4.855B | 12.25 |
| Prestige Consumer Healthcare (PBH) | United States | $3.744B | 16.73 |
| Perrigo (PRGO) | Ireland | $3.706B | 9.39 |
| Haemonetics (HAE) | United States | $3.485B | 15.88 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.307B | 27.48 |
| ICU Medical (ICUI) | United States | $3.014B | 22.23 |
| LeMaitre Vascular (LMAT) | United States | $1.802B | 40.29 |
| QuidelOrtho (QDEL) | United States | $1.721B | 11.84 |
| AtriCure (ATRC) | United States | $1.449B | 0.00 |
| Acuren (TIC) | United States | $1.408B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.244B | 12.63 |
| Phibro Animal Health (PAHC) | United States | $1.192B | 15.24 |
| Green Thumb Industries (GTBIF) | United States | $1.190B | 26.76 |
| Neogen (NEOG) | United States | $1.029B | 13.17 |
| BioLife Solutions (BLFS) | United States | $0.996B | 0.00 |
| InMode (INMD) | Israel | $0.878B | 8.85 |
| Kestra Medical Technologies (KMTS) | United States | $0.816B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.625B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.619B | 0.00 |
| Owens & Minor (OMI) | United States | $0.599B | 4.97 |
| Evolus (EOLS) | United States | $0.593B | 0.00 |
| CeriBell (CBLL) | United States | $0.563B | 0.00 |
| Valneva SE (VALN) | France | $0.557B | 0.00 |
| Surmodics (SRDX) | United States | $0.432B | 0.00 |
| SNDL (SNDL) | Canada | $0.405B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.315B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.314B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.298B | 10.97 |
| Quanterix (QTRX) | United States | $0.268B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.267B | 0.00 |
| Cerus (CERS) | United States | $0.260B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.257B | 21.63 |
| Aurora Cannabis (ACB) | Canada | $0.255B | 75.50 |
| OraSure Technologies (OSUR) | United States | $0.239B | 0.00 |
| ZimVie (ZIMV) | United States | $0.235B | 10.68 |
| Sanara MedTech (SMTI) | United States | $0.234B | 0.00 |
| Brainsway (BWAY) | Israel | $0.228B | 60.45 |
| Biote (BTMD) | United States | $0.220B | 6.18 |
| Canopy Growth (CGC) | Canada | $0.200B | 0.00 |
| High Tide (HITI) | Canada | $0.199B | 0.00 |
| Omeros (OMER) | United States | $0.197B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.195B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.180B | 14.69 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.149B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.110B | 0.00 |
| Jin Medical (ZJYL) | China | $0.103B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.80 |
| MacroGenics (MGNX) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Apyx Medical (APYX) | United States | $0.085B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.076B | 0.00 |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Safety Shot (SHOT) | United States | $0.055B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 14.52 |
| Nephros (NEPH) | United States | $0.039B | 52.07 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |